CU22835A3 - USEFUL LIVES OF VACCINES USEFUL FOR THE HIGH-LEVEL EXPRESSION OF O-ANTIGENS HETEROLOGISTS OF GRAM-NEGATIVE PATHOGENS AND DERIVED FROM THE SAME FOR USE AS LIVING VACCINES - Google Patents

USEFUL LIVES OF VACCINES USEFUL FOR THE HIGH-LEVEL EXPRESSION OF O-ANTIGENS HETEROLOGISTS OF GRAM-NEGATIVE PATHOGENS AND DERIVED FROM THE SAME FOR USE AS LIVING VACCINES

Info

Publication number
CU22835A3
CU22835A3 CU1998045A CU1998045A CU22835A3 CU 22835 A3 CU22835 A3 CU 22835A3 CU 1998045 A CU1998045 A CU 1998045A CU 1998045 A CU1998045 A CU 1998045A CU 22835 A3 CU22835 A3 CU 22835A3
Authority
CU
Cuba
Prior art keywords
vaccines
useful
strains
heterologous
heterologists
Prior art date
Application number
CU1998045A
Other languages
Spanish (es)
Inventor
Jean-Francois Viret
Stanley J Cryz
Didier Favre
Original Assignee
Schweiz Serum & Impfinst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst filed Critical Schweiz Serum & Impfinst
Priority to CU1998045A priority Critical patent/CU22835A3/en
Publication of CU22835A3 publication Critical patent/CU22835A3/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a cepas portadoras de vacunas gram negativas atenuadas vivas que son útiles para la expresión y suministro de antígenos o heterólogos (O-PS) de patógenos gram negativos. Dichas cepas son deficientes en la expresión de O-PS homólogos debido a una modificación genética definida, preferiblemente una supresión, y por lo tanto, son capaces de expresar eficientemente un O-PS heterólogo deseado en tal manera que se acopla covalentemente al lípido A del núcleo de LPS homólogo o heterólogo. La presente invención además se refiere a cepas portadoras de vacuna viva que contienen un gen heterólogo o un grupo de genes heterólogos que codifican O-PS. Preferiblemente, dichas cepas contienen adicionalmente genes necesarios para la síntesis de LPS heterólogo uniforme completo. La presenta invención también se refiere a vacunas vivas que comprenden dichas cepas, preferiblemente para la inmunización contra patógenos entéricos gram negativos.The present invention relates to live attenuated gram negative vaccine strains that are useful for the expression and delivery of antigens or heterologists (O-PS) of gram negative pathogens. Such strains are deficient in the expression of homologous O-PS due to a defined genetic modification, preferably a suppression, and therefore, are capable of efficiently expressing a desired heterologous O-PS in such a way that it covalently attaches to lipid A of the nucleus of homologous or heterologous LPS. The present invention also relates to live vaccine carrying strains that contain a heterologous gene or a group of heterologous genes encoding O-PS. Preferably, said strains additionally contain genes necessary for the synthesis of complete uniform heterologous LPS. The present invention also relates to live vaccines comprising said strains, preferably for immunization against gram negative enteric pathogens.

CU1998045A 1998-04-10 1998-04-10 USEFUL LIVES OF VACCINES USEFUL FOR THE HIGH-LEVEL EXPRESSION OF O-ANTIGENS HETEROLOGISTS OF GRAM-NEGATIVE PATHOGENS AND DERIVED FROM THE SAME FOR USE AS LIVING VACCINES CU22835A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU1998045A CU22835A3 (en) 1998-04-10 1998-04-10 USEFUL LIVES OF VACCINES USEFUL FOR THE HIGH-LEVEL EXPRESSION OF O-ANTIGENS HETEROLOGISTS OF GRAM-NEGATIVE PATHOGENS AND DERIVED FROM THE SAME FOR USE AS LIVING VACCINES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1998045A CU22835A3 (en) 1998-04-10 1998-04-10 USEFUL LIVES OF VACCINES USEFUL FOR THE HIGH-LEVEL EXPRESSION OF O-ANTIGENS HETEROLOGISTS OF GRAM-NEGATIVE PATHOGENS AND DERIVED FROM THE SAME FOR USE AS LIVING VACCINES

Publications (1)

Publication Number Publication Date
CU22835A3 true CU22835A3 (en) 2006-12-15

Family

ID=46599528

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1998045A CU22835A3 (en) 1998-04-10 1998-04-10 USEFUL LIVES OF VACCINES USEFUL FOR THE HIGH-LEVEL EXPRESSION OF O-ANTIGENS HETEROLOGISTS OF GRAM-NEGATIVE PATHOGENS AND DERIVED FROM THE SAME FOR USE AS LIVING VACCINES

Country Status (1)

Country Link
CU (1) CU22835A3 (en)

Similar Documents

Publication Publication Date Title
Chiang et al. Whole tumor antigen vaccines: where are we?
Saxena et al. Pre-existing immunity against vaccine vectors–friend or foe?
Brockstedt et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity
Raychaudhuri et al. Fully mobilizing host defense: building better vaccines
Donninger et al. Cancer vaccines: Promising therapeutics or an unattainable dream
Butkovich et al. Advancements in protein nanoparticle vaccine platforms to combat infectious disease
IL136131A0 (en) Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype
Hegazy et al. Salmonella enterica as a vaccine carrier
BR9712852A (en) Plasmid, composition, process of immunizing an individual against a pathogen, recombinant vaccine, live attenuated pathogen, substantially pure bl-1 protein, recombinant expression vector, and isolated antibody
Hegazy et al. Evaluation of Salmonella enterica type III secretion system effector proteins as carriers for heterologous vaccine antigens
MXPA05008340A (en) Modified free-living microbes, vaccine compositions and methods of use thereof.
Martínez-Puente et al. Plasmid DNA for therapeutic applications in cancer
CY1107950T1 (en) NAVIGATION VACCINE COMPOSITIONS AND METHODS
DE69632141D1 (en) LIVING VACCINES AGAINST GRAM-NEGATIVE PATHOGENES THAT EXPRESS HETEROLOGIST O-ANTIGENS
Jawalagatti et al. Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection
Wang et al. Optimization of antitumor immunotherapy mediated by type III secretion system-based live attenuated bacterial vectors
Zhou et al. T helper 2 immunity to hepatitis B surface antigen primed by gene‐gun‐mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif‐containing oligodeoxynucleotides
CU22835A3 (en) USEFUL LIVES OF VACCINES USEFUL FOR THE HIGH-LEVEL EXPRESSION OF O-ANTIGENS HETEROLOGISTS OF GRAM-NEGATIVE PATHOGENS AND DERIVED FROM THE SAME FOR USE AS LIVING VACCINES
Khare et al. SARS-CoV-2 vaccines: types, working principle, and its impact on thrombosis and gastrointestinal disorders
WO2018231078A3 (en) Production of rough-type salmonella enteritidis and the genetic modifications thereof for use as an avian vaccine
Weiss et al. Bacteria-mediated transfer of eukaryotic expression plasmids into mammalian host cells
Jones et al. Biomaterials at the interface of nano-and micro-scale vector–cellular interactions in genetic vaccine design
Bugybayeva et al. Development of human vectored brucellosis vaccine formulation: assessment of safety and protectiveness of influenza viral vectors expressing Brucella immunodominant proteins in mice and Guinea pigs
PH12020500526A1 (en) Paramyxoviridae expression system
IL148741A0 (en) Vaccine

Legal Events

Date Code Title Description
MK Ceased due to expiration of term